Welcome to our dedicated page for Ibex SEC filings (Ticker: IBEX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Looking for the story behind IBEX’s rapid expansion into AI-powered contact centers? Start with the disclosures investors trust most. Our SEC Filings hub untangles every IBEX document—whether you need the IBEX annual report 10-K simplified to gauge client concentration risk or an IBEX quarterly earnings report 10-Q filing to track segment margins.
Finding those details across hundreds of pages is tedious. Stock Titan applies AI that highlights wage inflation in nearshore sites, flags capital spending on the Wave iX platform, and provides instant alerts for IBEX insider trading Form 4 transactions. The result: understanding IBEX SEC documents with AI becomes a five-minute task.
Use the menu to jump straight to what professionals ask for most:
- Real-time Form 4 feed – follow IBEX executive stock transactions Form 4 and get context around each trade.
- 8-K event briefs – see IBEX 8-K material events explained minutes after they hit EDGAR, from new client wins to leadership changes.
- DEF 14A proxy tools – decode IBEX proxy statement executive compensation without spreadsheet gymnastics.
- Earnings pack – one click reveals our IBEX earnings report filing analysis and historical KPIs.
Every filing—10-K, 10-Q, 8-K, S-8, SC 13G, or the next IBEX Form 4 insider transactions real-time—arrives here within seconds of EDGAR publication and is paired with plain-English summaries. Monitor contract renewal clauses, compare headcount by region, or assess AI capital spend—all without sifting through dense legal text. Complex disclosures, made clear.
IBEX Ltd filed a Form 144 notifying a proposed sale of 697 common shares with an aggregate market value of $27,587.95, scheduled approximately for 10/02/2025. The filing shows 13,315,077 shares outstanding for the issuer and states the 697 shares were acquired on 09/30/2025 by vesting of a performance grant (2,347 shares noted as granted and vested on that date).
The filing also discloses prior sales by Paul Joseph Inson within the past three months: 10,000 shares on 08/22/2025 for $300,013.00, 255 shares on 08/26/2025 for $7,428.15, and 3,831 shares on 09/12/2025 for $149,179.14. The filer certifies no undisclosed material adverse information is known.
IBEX Ltd insider Christina Alice Trofimuk-O'Connor filed a Form 144 to sell 1,001 shares of common stock on NASDAQ with an aggregate market value of $39,621.33 and an approximate sale date of 10/02/2025. The filing states these shares were acquired by the filer on 09/30/2025 through the vesting of a performance grant totaling 3,228 shares and shows recent open-market disposals of 366 shares on 08/26/2025 for $10,661.58 and 844 shares on 09/16/2025 for $32,494.00. The filing includes the standard representation that the filer is not aware of undisclosed material adverse information about the issuer.
On 09/30/2025 IBEX Ltd director and Chief People Officer Paul Joseph Inson had 2,347 performance-based stock units (PSUs) certified for the period ending 06/30/2025 and converted into 2,347 common shares. To satisfy tax withholding from that vesting, the reporting person sold 697 shares on 10/02/2025 at a weighted average price of $39.581, executed in multiple trades priced between $39.34 and $40.01. After these transactions the reporting person beneficially owned 4,916 common shares. The Form 4 states the sale was required to cover tax obligations and not a discretionary trade.
Christina Alice Trofimuk-O'Connor, Chief Legal Officer of IBEX Ltd (IBEX), had 3,228 performance-based stock units (PSUs) vest and convert into common shares on 09/30/2025. To satisfy tax-withholding obligations tied to that vesting, she sold 1,001 shares on 10/02/2025 at a weighted-average price of $39.5817, leaving her with 13,954 shares beneficially owned. The Form 4 states the PSUs were earned after certification of performance for the period ending 06/30/2025, and the reported sale was not a discretionary trade but a tax-withholding sale.
On September 30, 2025 IBEX Ltd director and Chief Sales and CS Officer Bruce Neil Dawson had 3,228 performance-based stock units (PSUs) certified as earned for the period ending June 30, 2025 and converted to common shares, bringing his total ownership to 7,720 shares following that acquisition. A subsequent sale on October 2, 2025 disposed of 959 shares at a weighted-average price of $39.5824, reducing his direct holdings to 6,761 shares.
The Form 4 states the 3,228 shares were acquired on vesting of performance awards and the 959 shares were sold solely to satisfy tax withholding obligations, not as discretionary trades. The filing discloses the sales executed in multiple trades at prices between $39.34 and $40.01.
Julie K. Casteel, Chief Sales/Marketing Officer of IBEX Ltd (IBEX), had 3,228 performance-based stock units vest and convert to common shares on 09/30/2025, increasing her holdings to 29,123 shares.
On 10/02/2025 she sold 806 shares at a weighted average price of $39.583 to satisfy tax-withholding obligations, leaving her with 28,317 beneficially owned shares. The filing states the PSU vesting followed certification of performance goals for the period ending 06/30/2025.
IBEX Ltd's Chief Operating Officer, David Martin Afdahl, had 3,228 performance-based stock units (PSUs) vest and convert into common shares on 09/30/2025 after certification of performance goals for the period ending 06/30/2025. To satisfy tax-withholding obligations related to that vesting, the reporting person sold 1,103 shares on 10/02/2025 at a weighted average price of $39.5818 per share. As a result of these transactions, the reporting person’s beneficial ownership declined from 58,214 shares following the PSU conversion to 57,111 shares after the sale. The Form 4 states the sales were required to cover taxes and were not discretionary trades.
IBEX Ltd insider report: Chief Financial Officer Taylor C. Greenwald had 4,196 performance-based stock units (PSUs) vest and convert into common shares on 09/30/2025, bringing total beneficial ownership to 37,757 shares.
On 10/02/2025 the reporting person sold 1,275 shares at a weighted average price of $39.5819 to satisfy tax withholding obligations related to the PSU vesting, leaving 36,482 shares beneficially owned. The Form 4 states the sales were not discretionary trades but were required to cover taxes; the filer offers to provide trade-level price details on request.
Robert Thomas Dechant, Chief Executive Officer and a director of IBEX Ltd (IBEX), had 14,524 performance-based stock units (PSUs) convert to common shares on September 30, 2025 after certification of performance goals for the period ending June 30, 2025. To satisfy tax-withholding obligations related to that vesting, 6,711 shares were sold in multiple trades on October 2, 2025 at a weighted average price of $39.5817 per share. Following these transactions, the reporting person beneficially owns 199,812 common shares.
Form 144 notice for IBEX Ltd (IBEX) reports a proposed sale of 2,295 common shares with an aggregate market value of $93,475.69. The sale is listed on NASDAQ and the approximate sale date is 09/19/2025. The securities were acquired on 09/18/2025 by vesting of a grant from the issuer, with 7,500 shares shown as acquired on that date. A prior sale by the same person, Taylor C Greenwald, recorded 438 shares sold on 08/26/2025 for $12,757.51. Broker listed: Global Shares Financial Services Inc.
FAQ
What is the current stock price of Ibex (IBEX)?
What is the market cap of Ibex (IBEX)?
